Health-Related Quality of Life in Patients with Advanced Metastatic Melanoma: Results of a Randomized Phase III Study Comparing Temozolomide with Dacarbazine

References

• Koh H. K. Cutaneous melanoma. N. Engl. J. Med. 1991; 325: 171–182
   PubMed Web of Science ®Google Scholar
• Dreiling L., Hoffman S., Robinson W. A. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv. Intern. Med. 1996; 41: 553–604
   PubMedGoogle Scholar
• American Cancer Society. Cancer Facts and Figures – 2001. American Cancer Society, New York, NY 2001
   Google Scholar
• Cohen G. L., Falkson C. I. Current treatment options for malignant melanoma. Drugs 1998; 55(6)791–799
   PubMed Web of Science ®Google Scholar
• Balch C. M., Houghton A., Peters L. J. Cutaneous melanoma in cancer. Cancer: Principles and Practices in Oncology4th Ed., S. DeVita, Jr., Hellman, A. S. Rosenberg. Lippincott, Philadelphia 1989; 1612–1661
   Google Scholar
• Touloukian C. E., Rosenberg S. A. A survey of treatments used in patients with metastatic melanoma: analysis of 189 patients referred to the National Cancer Institute. Cancer J. Sci. Am. 1999; 5(5)269–274
   PubMed Web of Science ®Google Scholar
• Malignant Tumors of the Skin, A. C. Chu, R. L. Edelson. Arnold, London 1999
   Google Scholar
• Kleeberg U. R., Engel E., Israels P., Brocker E. B., Tilgen W., Kennes C., Gerard B., Lejeune F., Glabbeke M. V., Lentz M. A. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and effectiveness. A multi-centre phase II trial of the EORTC-melanoma Cooperative Group (MCG). Melanoma Res. 1995; 5: 195–200
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Seipp C. A., Einhorn J. H., White D. E., Steinberg S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J. Clin. Oncol. 1999; 17(3)968–975
   PubMed Web of Science ®Google Scholar
• Schmittle A., Keilholz U., Max R., Thiel E., Scheibenbogen C. Induction of tyrosinase-reactive T cells by treatment with dacaraazine, cisplatin, interferon-alpha ± interleukin-2 in patients with metastatic melanoma. Int. J. Cancer 1999; 80: 39–43
   PubMed Web of Science ®Google Scholar
• Middleton M. R., Grob J. J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000; 18(1)158–166
   PubMed Web of Science ®Google Scholar
• Chapman P. B., Einhorn L. H., Meyers M. L., Saxman S., Destro A. N., Panageas K. S., Begg C. B., Agarwala S. S., Schuchter L. M., Ernstoff M. S., Houghton A. N., Kirkwood J. M. Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 1999; 17(9)2745–2751
   PubMed Web of Science ®Google Scholar
• Revicki D. A., Osoba D., Fairclough D., Barofsky I., Berzon R., Leidy N. K., Rothman M. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res. 2001; 9: 887–900
   Web of Science ®Google Scholar
• King M. T. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual. Life Res. 1996; 5: 555–567
   PubMed Web of Science ®Google Scholar
• Osoba D., Rodrigues G., Myles J. Interpreting the significance of changes in health related quality of life scores. J. Clin. Oncol. 1998; 16: 139–144
   PubMed Web of Science ®Google Scholar
• Kazis L. E., Anderson J. J., Meenan R. F. Effect sizes for interpreting changes in health status. Med. Care 1989; 27: 178–189
   PubMed Web of Science ®Google Scholar
• Fitzsimmons D., George S., Payne S., Johnson C. D. Differences in perception of quality of life issues between health professionals and patients with pancreatic cancer. Psycho-oncology 1999; 8: 135–143
   PubMed Web of Science ®Google Scholar
• Chang V. T., Hwang S. S., Feuerman M., Kasimis B. S. Symptom and quality of life of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 2000; 88: 1175–1183
   PubMed Web of Science ®Google Scholar
• Portenoy R. K., Thaler H. T., Kornblith A. B., Lepore J. M., Friedlander-Klar H., Kiyasu E., Sobell K., Coyle N., Kemeny N., Norton L. Memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics, and distress. Eur. J. Cancer 1994; 30A: 326–1336
   Google Scholar
• Leidy N. K., Jonas D. L., Margolis M. K., Heyes A., Jones K., Silberman C. On health-related quality of life, symptoms, and the complementary nature of two patient-reported outcomes. Paper presented at the DIA Quality of Life Symposium. Hilton Head SC. 2001
   Google Scholar
• Osoba D. Health-related quality-of-life assessment in clinical trials of supportive care in oncology. Support Care Cancer 2000; 8: 84–88
   PubMed Web of Science ®Google Scholar
• Liu G., Franssen E., Fitch M. I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 1997; 15(1)110–115
   PubMed Web of Science ®Google Scholar
• DeMario M. D., Ratain M. J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol. 1998; 16(7)2557–2567
   PubMed Web of Science ®Google Scholar
• Fairclough D. L. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat. Med., 16: 1197–1209
   PubMed Web of Science ®Google Scholar
• Fairclough D. L., Peterson H. F., Cella D., Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat. Med. 1998; 17: 781–796
   PubMed Web of Science ®Google Scholar